Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I dose escalating trial of bortezomib (Velcade) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia

Phase I dose escalating trial of bortezomib (Velcade) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood. 2004; 104:498a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.